Innovative drug stocks on the Hong Kong market performed strongly, with Ascletis Pharma (01672.HK) rising more than 9%, and Innovent Biologics (01801.HK), BeiGene (06160.HK), and Genting New Horizon (01952.HK) all gaining more than 5%. Zai Lab (09688.HK), SinoBiopharm (01530.HK) rose more than 4%.